Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant
Keywords: Abuse potential; Drug dependence; Drug discrimination; Methods; MK-4305; Orexin receptor antagonist; Preclinical drug development; Self-administration; Suvorexant; Withdrawal; ANOVA; analysis of variance; AUC0-24h; area under the curve during 24Â h; BLQ